Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 +/- Bevacizumab in Cervical Cancer
NCT05179239Phase 3Terminated
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Feb 2022
- Primary completion
- Aug 2024
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of retlirafusp alfa in Cervical Cancer (CC) (3 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Incidence and severity of Participants Who Experience an Adverse Event (AE) at 26 months, Incidence and severity of Participants Who Experience a Serious AE (SAE) at 26 months and 3 more. Started Feb 2022; status: terminated.
02
Drugs
retlirafusp alfa
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05179239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05179239.